198995-91-4

Usage

Uses

There is limited information available on the uses of BENZYL 3-OXOCYCLOBUTANECARBOXYLATE, indicating that it may not be widely used or studied. However, given its chemical structure and classification, it is possible that it could be utilized in various applications within the chemical, pharmaceutical, or materials science industries. These potential uses may include:
Used in Chemical Research:
BENZYL 3-OXOCYCLOBUTANECARBOXYLATE is used as a research compound for [application reason], such as studying its chemical properties, reactivity, or potential as an intermediate in the synthesis of other compounds.
Used in Pharmaceutical Development:
BENZYL 3-OXOCYCLOBUTANECARBOXYLATE is used as a pharmaceutical intermediate for [application reason], potentially serving as a building block in the development of new drugs or therapeutic agents.
Used in Materials Science:
BENZYL 3-OXOCYCLOBUTANECARBOXYLATE is used as a component in the development of new materials for [application reason], such as in the creation of novel polymers or composites with unique properties.

Upstream product

• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 501-53-1 benzyl chloroformate 
• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 

Downstream Products

• 935273-86-2 benzyl 3,3-difluorocyclobutane-1-carboxylate 
• 98231-07-3 3,3-dimethoxycyclobutanecarboxylic acid methyl ester 
• 1303609-20-2 benzyl trans-3-hydroxy-3-methylcyclobutanecarboxylate 
• 128041-58-7 cis-benzyl 3-hydroxycyclobutanecarboxylate 
• 128041-58-7 trans-benzyl 3-hydroxycyclobutanecarboxylate 
• 1438249-51-4 benzyl 3-[(5-bromopyridin-2-yl)oxy]cyclobutanecarboxylate 
• 1438249-52-5 benzyl 3-{[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]oxy}cyclobutanecarboxylate 
• 1438250-68-0 benzyl 3-({5-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-2,3'-bipyridin-6'-yl}oxy)cyclobutanecarboxylate 

Relevant academic research and scientific papers

Diastereoselective Synthesis of a cis-1,3-Disubstituted Cyclobutane Carboxylic Acid Scaffold for TAK-828F, a Potent Retinoic Acid Receptor-Related Orphan Receptor (ROR)-γt Inverse Agonist

A scalable synthesis of the cis-1,3-disubstituted cyclobutane carboxylic acid scaffold of TAK-828F (1) has been developed, featuring the diastereoselective reduction of a cyclobutylidene Meldrum's acid derivative with NaBH4. Controlling acidic impurities was crucial for improving the diastereomeric ratio by recrystallization. Furthermore, reaction optimization and the streamlining of several steps established a scalable synthetic method free from column chromatography purification with an overall yield improved from 23 to 39%.

Two Scalable Syntheses of 3-(Trifluoromethyl)cyclobutane-1-carboxylic Acid

Two efficient synthetic methods for preparation of 3-(trifluoromethyl)cyclobutane-1-carboxylic acid are reported starting from readily available 4-oxocyclobutane precursors. These cyclobutanones can be converted to their CF3 carbinols upon treatment with TMSCF3 and a fluoride source. The bis-carboxylate system 9 was deoxygenated by treatment of Bu3SnH and provided desired compound 1 upon decarboxylation. In the monocarboxylate system 15, the triflate could be efficiently eliminated; subsequent hydrogenation afforded cis-1.

PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

METHOD FOR PRODUCING HETEROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a production method suitable for industrial production of a compound (A). SOLUTION: A compound (A) or a salt thereof is produced in an increased total yield and at low cost, with a reduced number of steps, and without requiring cryogenic reaction conditions or complex operation such as column purification or chiral column purification [where each symbol is as described in the specifications]. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPO&INPIT

Bicyclobutane carboxylic amide as a cysteine-directed strained electrophile for selective targeting of proteins

Expanding the repertoire of electrophiles with unique reactivity features would facilitate the development of covalent inhibitors with desirable reactivity profiles. We herein introduce bicyclo[1.1.0]butane (BCB) carboxylic amide as a new class of thiol-reactive electrophiles for selective and irreversible inhibition of targeted proteins. We first streamlined the synthetic routes to generate a variety of BCB amides. The strain-driven nucleophilic addition to BCB amides proceeded chemoselectively with cysteine thiols under neutral aqueous conditions, the rate of which was significantly slower than that of acrylamide. This reactivity profile of BCB amide was successfully exploited to develop covalent ligands targeting Bruton's tyrosine kinase (BTK). By tuning BCB amide reactivity and optimizing its disposition on the ligand, we obtained a selective covalent inhibitor of BTK. The in-gel activitybased protein profiling and mass spectrometry-based chemical proteomics revealed that the selected BCB amide had a higher target selectivity for BTK in human cells than did a Michael acceptor probe. Further chemical proteomic study revealed that BTK probes bearing different classes of electrophiles exhibited distinct off-target profiles. This result suggests that incorporation of BCB amide as a cysteine-directed electrophile could expand the capability to develop covalent inhibitors with the desired proteome reactivity profile.

JAK INHIBITORS

Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.

Lactonization reactions through hydrolase-catalyzed peracid formation. Use of lipases for chemoenzymatic Baeyer-Villiger oxidations of cyclobutanones

A one-pot chemoenzymatic method has been described for the synthesis of γ-butyrolactones starting from the corresponding ketones through a Baeyer-Villiger reaction. The approach is based on a lipase-catalyzed perhydrolysis for the formation of peracetic acid, which is the responsible for the ketone oxidation. Optimization studies have been performed in the oxidation of cyclobutanone, finding Candida antarctica lipase type B, ethyl acetate and urea-hydrogen peroxide complex as the best system. The relative ratio of these reagents has also been analyzed in depth. This synthetic approach has been successfully extended to a family of 3-substituted cyclobutanones in high substrate concentration, yielding the corresponding lactones with excellent isolated yields and purities, under mild reaction conditions and after a simple extraction protocol.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.